CA2116138C - Methodes et compositions pour l'attenuation du rejet de xenogreffes medie par des anticorps chez des receveurs humains
- Google Patents
Methodes et compositions pour l'attenuation du rejet de xenogreffes medie par des anticorps chez des receveurs humains
Download PDF
Info
Publication number
CA2116138C
CA2116138CCA002116138ACA2116138ACA2116138CCA 2116138 CCA2116138 CCA 2116138CCA 002116138 ACA002116138 ACA 002116138ACA 2116138 ACA2116138 ACA 2116138ACA 2116138 CCA2116138 CCA 2116138C
Authority
CA
Canada
Prior art keywords
fwdarw
beta
gal
alpha
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alberta Research Council
Integris Baptist Medical Center Inc
Original Assignee
Alberta Research Council
Integris Baptist Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alberta Research Council, Integris Baptist Medical Center IncfiledCriticalAlberta Research Council
Priority claimed from PCT/US1992/007071external-prioritypatent/WO1993003735A1/fr
Publication of CA2116138A1publicationCriticalpatent/CA2116138A1/fr
Application grantedgrantedCritical
Publication of CA2116138CpublicationCriticalpatent/CA2116138C/fr
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
CA002116138A1991-08-231992-08-21Methodes et compositions pour l'attenuation du rejet de xenogreffes medie par des anticorps chez des receveurs humains
Expired - Fee RelatedCA2116138C
(fr)
Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man
CHARACTERIZATION OF HUMAN XENOREACTIVE ANTIBODIES IN LIVER FAILURE PATIENTS EXPOSED TO PIG HEPATOCYTES AFTER BIOARTIFICIAL LIVER TREATMENT: An Ex Vivo Model of Pig to Human Xenotransplantation: 1, 2
Méthode d'induction d'immunocytes antitumoraux, procédé de production d'immunocytes antitumoraux et immunocytes antitumoraux produits par le procédé
The structural complexity and animal tissue distribution of N-glycolylneuraminic acid (Neu5Gc)-terminated glycans. Implications for their immunogenicity in clinical xenografting